Revel Pharmaceuticals
Revel develops and commercializes therapeutic enzymes to treat age-related diseases and molecular damage.
Founded
2019Revel develops and commercializes therapeutic enzymes to treat age-related diseases and molecular damage.
Revel Pharmaceuticals, founded with the mission to combat age-related diseases, focuses on developing and commercializing therapeutic enzymes. The company aims to address various conditions such as osteoarthritis, kidney disease, cardiovascular disease, skin aging, and diabetes complications by targeting and degrading age-associated molecular damage. Their innovative approach seeks to improve the quality of life for aging populations by offering cutting-edge therapeutic solutions.
Notable figures associated with Revel Pharmaceuticals include leading scientists and industry experts in biotechnology and pharmaceuticals. The company has attracted significant interest from investors focused on longevity and healthcare innovation. Key achievements include advancing their enzyme therapies through critical stages of development and securing patents for their proprietary technologies. Revel Pharmaceuticals is poised to make a substantial impact on the treatment of age-related diseases, contributing to the broader field of regenerative medicine.
Companies similar to Revel Pharmaceuticals include Retro Biosciences, Rejuveron Life Sciences, Repair Biotechnologies and Reven Holdings.
Revel Pharmaceuticals was founded in 2019.
Revel Pharmaceuticals' headquarters is located in San Francisco, CA, US.
Revel Pharmaceuticals' most recent funding round was for $8.4M (USD) in March 2022.
As of Mar 17, 2022, Revel Pharmaceuticals has disclosed funding of $8.4M (USD). Undisclosed round amounts are excluded.
Revel Pharmaceuticals has 6 employees as of Feb 5, 2024.
Reven Holdings
reven.com
